Clearmind Medicine (CMND) Long-Term Investments (2021 - 2022)
Clearmind Medicine (CMND) posted quarterly Long-Term Investments of $486176.2 for Q4 2022, up 290.39% year-over-year from $124535.3 in Q4 2021, and up 290.39% quarter-over-quarter from $124535.3 in Q4 2021.
Clearmind Medicine (CMND) Long-Term Investments (2021 - 2022) Analysis & Trends
Clearmind Medicine's Long-Term Investments history runs 2 years deep, the most recent figure standing at $486176.2 for Q4 2022.
- In Q4 2022, Long-Term Investments rose 290.39% year-over-year to $486176.2; the TTM figure through Oct 2022 stood at $486176.2 (up 290.39% YoY), while the FY2022 annual figure was $502028.7, up 303.22% from the prior year.
- Long-Term Investments for Q4 2022 stood at $486176.2, up from $124535.3 in the prior quarter.
- The five-year high for Long-Term Investments was $486176.2 in Q4 2022, with the low at $124535.3 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 372.10 Mn |
| 10 | Clearmind Medicine | 537,435.54 | -13.06 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Oct 31, 2022 | 486,176.20 |
| Oct 31, 2021 | 124,535.33 |